COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Clients save Millions in Drug Spend through the use of Innovative Pharmacy Analytics for Hospitals and Health Systems22/10/2018
-   
  Kura Oncology Presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC22/10/2018
-   
  Novo Nordisk A/S - Share repurchase programme22/10/2018
-   
  Cybrexa Therapeutics Expands Scientific Advisory Board Ahead of IND Filing22/10/2018
-   
  Transactions under Novozymes’ stock buyback program22/10/2018
-   
  Corvus Pharmaceuticals Announces New Data on Adenosine Gene Signature Biomarker Associated with Patient Response to CPI-444 at European Society for Medical Oncology (ESMO) 2018 Congress22/10/2018
-   
  Hemispherx Outlines Ampligen Combination Therapy Clinical Study Strategy for the Treatment of Multiple Cancers in Letter to Stockholders22/10/2018
-   
  Resverlogix Announces Participation at Premier Kidney, Alzheimer’s Disease and Cardiovascular Conferences22/10/2018
-   
  MyoKardia to Host R&D Day on October 30, 201822/10/2018
-   
  VistaGen Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 201822/10/2018
-   
  Arbutus Names New Members to its Board of Directors22/10/2018
-   
  Nuvectra® to Report Third Quarter 2018 Financial Results on October 29, 201822/10/2018
-   
  Sharp Rees-Stealy Medical Group leverages Allscripts EHR to achieve HIMSS Analytics O-EMRAM Stage 722/10/2018
-   
  Dentsply Sirona to Host Third Quarter 2018 Conference Call on November 8th22/10/2018
-   
  Relypsa Announces Presentation of New Clinical and Real-World Analyses of Veltassa® at AMCP Nexus 201822/10/2018
-   
  Results from Celtaxsys’ Acebilustat Phase 2 Trial in Cystic Fibrosis Patients Showing Clinically Meaningful Improvement in Pulmonary Exacerbations Presented at the North American Cystic Fibrosis Conference22/10/2018
-   
  Allena Pharmaceuticals Presents Preclinical Data Demonstrating Normalized Urine Uric Acid Excretion and Plasma Urate Reduction Following Treatment with ALLN-34622/10/2018
-   
  Inovio Presents Progression Free Survival & PSA Doubling Time Improvements in Prostate Cancer Patients Treated with INO-515022/10/2018
-   
  Opiant Pharmaceuticals to Participate in Opioid Panel at the BARDA Industry Day22/10/2018
Pages